Week in Review: Hansoh In-licenses Endometriosis/Fibroid Therapy in $170 Million Deal
publication date: Aug 13, 2022
Deals and Financings
- Shanghai Hansoh Pharma acquired Greater China rights to a therapy for endometriosis and uterine fibroids from Korea’s TiumBio in a $170 million deal;
- Insilico Medicine, a Hong Kong-based AI drug discovery company, closed a $35 million D2 round led by Aramco Ventures’ growth fund that will expand Insilico’s AI focus into new areas;
- Shanghai Epigenic Therapeutics raised $20 million in Angel and Pre-A fundings to develop new therapies using gene editing technology that regulates the epigenetic genome;
- Singapore’s Axcynsis Therapeutics, an ADC company formed six months ago, established an R&D center in Shanghai and raised $15 million in seed financing;
Trials and Approvals
- LianBio completed enrollment in a China Phase III trial of mavacamten in patients with obstructive hypertrophic cardiomyopathy;
- Boston’s EQRx started a US Phase III trial of its in-licensed EGFR therapy for lung cancer patients, which EQRx acquired from China’s Hansoh;
- Nanjing Frontier Biotech announced positive results from a Phase I trial of its COVID-19 therapy, a small molecule inhibitor of coronavirus main protease;
- Arbele, a US-China immunotherapy company, dosed the first patient in an Australian Phase I trial of a bispecific for patients with advanced gastrointestinal cancers;
- Inmagene Biopharma and HutchMed started a global Phase I trial of their partnered BTK inhibitor for immunological diseases;
- Shenzhen ImmVira reported its oncolytic herpes simplex virus product was granted Orphan Drug Designation in the US to treat malignant glioma.
Stock Symbols: (HK: 3692) (NSDQ: LIAN) (NSDQ/AIM: HCM; HK: 13)
Share this with colleagues:
Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?
If you are already a subscriber, please login.
If you believe you should have received this message in error, please contact us.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
